Overall, while the consequences of fratricide for anti-SLAMF7 CAR T cells and other immune cells require further investigation, these studies suggest that anti-SLAMF7 CAR T cells could be a promising therapeutic strategy for treating myeloma. This evidence concerns the gene SLAMF7 and plasma cell myeloma.